Sprint Bioscience: Sprint Bioscience enters a VADA licensing agreement - Redeye

Redeye endorses yesterday's news that Sprint Bioscience has licensed the global rights to its cancer program VADA (VRK1) to Day One Biopharmaceuticals. We will return with a more in-depth take in a research update.

Länk till analysen i sin helhet: https://www.redeye.se/research/933000/sprint-bioscience-sprint-bioscience-enters-a-vada-licensing-agreement?utm_source=finwire&utm_medium=RSS